Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback

Hikma Pharmaceuticals PLC raised its dividend by 5% for 2025 and launched a $250 million share buyback program, while targeting $5 billion in group revenue by 2030.

Hikma Pharmaceuticals PLC announced a 5% dividend increase for 2025 and initiated a $250 million share buyback, alongside a long-term goal to reach $5 billion in group revenue by 2030. These moves signal confidence in cash generation and shareholder returns, as outlined in recent CEO commentary published on April 24, 2026, ad-hoc-news.de as of April 2026.

The updates come amid steady performance in key markets, drawing interest from US investors through its ADR listing and exposure to North American generics demand. Hikma maintains investment-grade ratings while pursuing growth in complex injectables and respiratory products.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Hikma Pharmaceuticals PLC
• Sector/industry: Healthcare, drug manufacturers – specialty and generic
• Headquarters/country: United Kingdom
• Core markets: North America, Middle East and North Africa, United Kingdom, Europe
• Key revenue drivers: Generic injectables, oral and respiratory generics, branded products
• Home exchange/listing venue: London Stock Exchange (HIK)
• Trading currency: GBP

Hikma Pharmaceuticals PLC: core business model

Hikma Pharmaceuticals PLC develops, manufactures, and markets generic, branded, and non-branded pharmaceuticals across three segments: injectables, generics, and branded products, according to Morningstar’s company profile as of May 8, 2026, Morningstar as of May 8, 2026. The injectables unit focuses on sterile products for hospitals, while generics target oral solids, nasal, and inhalation therapies.

Branded operations emphasize high-value products in emerging markets like the Middle East and North Africa. This diversified model supports resilience amid pricing pressures in US generics.

Main revenue and product drivers for Hikma Pharmaceuticals PLC

North America drives the largest share of revenue, followed by MENA, UK, and Europe, per Morningstar’s regional data as of May 8, 2026. Hikma’s US subsidiary, Hikma Rx, leads growth in oral, nasal, and inhalation generics, shifting toward complex formulations and contract manufacturing for higher margins.

Injectables remain a cornerstone, with ongoing investments in capacity to meet hospital demand. Branded sales in MENA provide stable cash flow, complementing volatile US generics exposure relevant to US investors tracking pharma supply chains.

Dividend, buyback and growth plan to 2030

The 5% dividend hike for 2025 and $250 million buyback underscore capital return priorities, per CEO Said Darwazah’s April 24, 2026 commentary via Marketscreener, Marketscreener as of April 24, 2026. These initiatives align with investment-grade ratings and robust cash flow.

Group revenue ambitions of $5 billion by 2030 rely on North American expansion, complex generics, and portfolio discipline. US investors benefit via ADR access to this growth trajectory.

Why Hikma Pharmaceuticals PLC matters for US investors

Hikma’s strong US footprint in generics and injectables positions it as a key supplier in the world’s largest pharma market. Its ADR listing facilitates easy access for American portfolios seeking diversified healthcare exposure beyond pure US plays.

With North America as top revenue source, Hikma offers indirect bets on US hospital spending and generic penetration trends.

Conclusion

Hikma Pharmaceuticals PLC’s recent 5% dividend increase, $250 million buyback, and $5 billion revenue target by 2030 highlight a balanced approach to growth and shareholder returns. North American generics strength bolsters its appeal for US investors amid global pharma dynamics.

Diversified segments and regional exposure provide stability, though execution on complex products remains key. Ongoing capital discipline supports long-term value creation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.